Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| American Society for Gastrointestinal Endoscopy | OTHER |
| University of California, Los Angeles | OTHER |
| University of Michigan | OTHER |
| Exact Sciences Corporation |
Not provided
Not provided
Not provided
Not provided
Not provided
This study plans to learn more about what patients think about screening for esophageal cancer (EAC) and Barrett's esophagus (BE); a pre-cancerous condition associated with esophageal cancer. The plan is to use this information to modify screening practices in the United States with the goal to decrease the number of people who die from esophageal cancer.
To achieve this goal, patient preferences for BE/EAC screening tests will be evaluated through a prospective multicenter discrete choice-based conjoint survey. Patients will choose between a series of hypothetical options and rank their priorities and what they value according to differences in benefit of detection (sensitivity), convenience (time, setting), screening related physical harms (procedural discomfort), and financial harms. By evaluating relative importance of test characteristics and patient prioritization the study will (1) define patient preferences and barriers for attributes of BE/EAC screening modalities to elicit the overall preferred test as well as differences in each attribute that informed that choice and (2) characterize differences in BE/EAC test preferences by patient sociodemographic characteristics (age, sex, race, ethnicity) and by the presence or absence of gastroesophageal reflux disease (GERD).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients | 556 eligible patients will be recruited across 5 participating sites to complete a discrete choice-based conjoint survey. The survey will be distributed to eligible patients via Sawtooth internet survey at the time of a clinic appointment or remotely via video chat. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Patient survey | Behavioral | To assess patient preferences and barriers for attributes of BE/EAC screening modalities patients will complete a survey evaluating 5 domains: benefit of detection (sensitivity), convenience (time, setting), screening related physical harms (procedural discomfort), and financial harms. Prior to distribution, the survey will be refined and pretested among a sample of 5 patients. |
| Measure | Description | Time Frame |
|---|---|---|
| Define patient preferred BE/EAC screening test and barriers for attributes of BE/EAC screening tests | A discrete choice-based conjoint analysis survey evaluating 5 domains: benefit of detection (sensitivity), convenience (time, setting), screening related physical harms (procedural discomfort), and financial harms will be used to determine the relative importance of BE/EAC screening test characteristics and patient priorities. Survey data will be reported in aggregate and factors and choices will be analyzed using the Fisher Exact and Mann-Whitney rank-sum tests. This approach will elicit the overall preferred test and differences in each test attribute that informed the patients choice. | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Characterization of differences in BE/EAC test preferences by patient sociodemographic characteristics and by patient presence or absence of GERD | Using the discrete choice-based conjoint analysis survey analysis, a logistic regression model of patient-specific attributes (age, sex, race, ethnicity) and by presence or absence of GERD will be used to evaluate if disparities in patient demographics or heath history impact complex decision making. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with 3 or more established risk factors for BE who have at least one outpatient clinic visit at a participating site. Patients will be identified at primary care and family medicine clinics. Patients with prior diagnosis of BE/EAC will be excluded. Across the 5 sites, planned enrollment is 556.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Alexa DeBord, MS | Contact | 303-724-0432 | alexa.debord@cuanschutz.edu |
| Name | Affiliation | Role |
|---|---|---|
| Sachin Wani, MD | University of Colorado, Denver | Principal Investigator |
| Jennifer Kolb, MD, MS | University of California, Los Angeles | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Colorado Anschutz Medical Campus | Recruiting | Aurora | Colorado | 80045 | United States |
Individual participant data that underlie the results reported in original publications after deidentification (text, tables, figures, appendixes).
9 months to 36 months following article publication.
Researchers who provide a methodologically sound proposal and investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.
These data can only be used for individual participant data meta-analysis.
Not provided
Not provided
| ID | Term |
|---|---|
| D005764 | Gastroesophageal Reflux |
| D001471 | Barrett Esophagus |
| ID | Term |
|---|---|
| D015154 | Esophageal Motility Disorders |
| D003680 | Deglutition Disorders |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |
Not provided
Not provided
| INDUSTRY |
| VA Medical Center-West Los Angeles | FED |
| University of Texas Southwestern Medical Center | OTHER |
Not provided
Not provided
Not provided
|
| Baseline |
| D004066 | Digestive System Diseases |
| D011230 | Precancerous Conditions |
| D009369 | Neoplasms |